Abstract
The potential benefit of hormone replacement therapy (HRT) has been superceded by the concern of increased risk in breast cancer incidence. Analysis of the world’s literature concluded that ever users of HRT had an overall risk of breast cancer of 1.14. Current users for 5 or more years had a relative risk of 1.35 and the risk increased with increasing duration of use. The Women’s Health Initiative (WHI) concluded that conjugated equine estrogen combined with progestogen (medroxyprogesterone acetate, MPA) therapy has a small but significant effect on breast cancer risk.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
